Skip navigation

Black tea


What is it?

Black tea is a product made from the Camellia sinesis plant. The aged leaves and stems are used to make medicine. Green tea, which is made from fresh leaves of the same plant, has some different properties.

Black tea is used for improving mental alertness as well as learning, memory and information processing skills. It is also used for treating headache and low blood pressure; preventing heart disease, including “hardening of the arteries” (atherosclerosis) and heart attack; preventing Parkinson's disease; and reducing the risk of stomach and colon cancer, lung cancer, ovarian cancer, and breast cancer. It is also used for type 2 diabetes, stomach disorders, vomiting, diarrhea, and as a diuretic to increase urine flow. Some people use black tea for preventing tooth decay and kidney stones. In combination with various other products, black tea is used for weight loss.

In foods, black tea is consumed as a hot or cold beverage.

How effective is it?

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for BLACK TEA are as follows:

Likely effective for...

  • Mental alertness. Drinking black tea and other caffeinated beverages throughout the day helps to keep people alert, even after extended periods without sleep.

Possibly effective for...

  • Hardening of the arteries (atherosclerosis). Early research shows that people who drink black tea seem to have a reduced risk of having their arteries become hardened. This link is stronger in women than men.
  • Low blood pressure after eating (postprandial hypotension). Drinking beverages containing caffeine, such as black tea, helps increase blood pressure in older people who have low blood pressure after eating.
  • Kidney stones. Women who drink black tea seem to have an 8% lower risk of developing kidney stones.
  • Heart attacks. Some research shows that people who drink black tea have a lower risk of having a heart attack. Also, people who have been drinking black tea for at least a year before having a heart attack seem to be less likely to die after having a heart attack.
  • Brittle bones (osteoporosis). Early research shows that older women who drink more black tea seem to have stronger bones. Drinking more black tea also seems to be linked with a lower risk of hip fracture in older men and women.
  • Ovarian cancer. Women who regularly drink tea, including black tea or green tea, appear to have a lower risk of developing ovarian cancer compared to women who never or rarely drink tea.
  • Parkinson's disease. Some research shows that people who drink caffeinated beverages such as coffee, tea, and cola have a lower risk of Parkinson's disease. The lower risk seems to be directly related to the dose of caffeine in men but not women. Drinking black tea also appears to be linked with a reduced risk of Parkinson's disease among people who smoke cigarettes.

Possibly ineffective for...

  • Breast cancer. People who drink black tea do not seem to have a lower risk of breast cancer.
  • Colon and rectal cancer. Some early research suggests that drinking black or green tea might be linked with a lower risk of colon and rectal cancer. However, most research shows that drinking tea is not linked with a lower risk of colon and rectal cancer. In fact, some early research suggests that drinking higher amounts of black tea might be linked with an increased risk of colon and rectal cancer.
  • Diabetes. Early research suggests that taking an extract of black and green tea does not improve HbA1C levels in people with diabetes. HbA1C is a measure of blood sugar control. Other early research suggests that drinking at least one cup of black tea per day is not linked with a lower risk of developing type 2 diabetes in Japanese adults.
  • Stomach cancer. Some early research suggests that drinking black or green tea might be linked with a lower risk of stomach cancer. However, most research shows that people who drink black or green tea do not have a lower risk. In fact, some early research suggests that drinking higher amounts of black tea might be linked with an increased risk of stomach cancer.
  • High cholesterol. Some research shows that black tea might reduce total cholesterol and low-density lipoprotein (LDL or “bad”) cholesterol in people with normal or high cholesterol levels. However, most research shows that drinking black tea does not have these effects.
  • High blood pressure. Some early research suggests that people who regularly drink green or black tea have a lower risk of having high systolic blood pressure, which is the top number of a blood pressure reading. However, most research shows that drinking black tea does not reduce blood pressure in people with normal or high blood pressure.

Insufficient evidence to rate effectiveness for...

  • Bladder cancer. Some early research suggests that people who drink black or green tea might have a lower risk of urinary tract cancers. However, other research shows that drinking black tea is not linked with a reduced risk of bladder cancer.
  • Heart disease. Some early research suggests that people who regularly drink black tea have a lower risk of developing heart disease. However, other research suggests that drinking black tea is linked with an increased risk of heart disease becoming worse or causing death.
  • Cavities. Early research suggests that rinsing with a black tea extract might prevent cavities.
  • Kidney cancer. Early research suggests that people who drink more black or green tea have a higher risk of developing kidney cancer.
  • Lung cancer. Green tea and black tea contain chemicals called phytoestrogens. Some research shows that men who get more phytoestrogens in their diet have a lower risk of developing lung cancer than men who do not get these chemicals. However other early research suggests that drinking black tea is not linked with a reduced risk of lung cancer and may even be linked with an increased risk.
  • Mouth cancer. Early research shows that black tea might help prevent mouth cancer in patients with lesions in the mouth that may turn into cancer.
  • Pancreatic cancer. Some early research suggests that drinking black tea is linked with a reduced risk of pancreatic cancer risk. However, other research shows conflicting results.
  • Prostate cancer. Early evidence suggests that drinking black tea is linked with a reduced risk of prostate cancer.
  • Stress. Early research suggests that drinking black tea for 6 weeks does not improve blood pressure, heart rate, or feelings of stress ratings while performing stressful tasks.
  • Stroke. Black tea contains chemicals called flavonoids. Early research suggests that eating a diet that contains flavonoids is linked with a lower risk of stroke.
  • Weight loss. Early research suggests that taking a combination product containing black tea extract plus green tea extract, asparagus, guarana, kidney bean, and mate along with a combination of kidney bean pods, garcinia, and chromium yeast for 12 weeks does not reduce body weight in overweight adults.
  • Stomach disorders.
  • Vomiting.
  • Diarrhea.
  • Headache.
  • Other conditions.
More evidence is needed to rate the effectiveness of black tea for these uses.

How does it work?

Return to top
Black tea contains 2% to 4% caffeine, which affects thinking and alertness, increases urine output, and may reduce the symptoms of Parkinson's disease. It also contains antioxidants and other substances that might help protect the heart and blood vessels.

Are there safety concerns?

Return to top
Drinking moderate amounts of black tea is LIKELY SAFE for most adults.

Drinking too much black tea, such as more than five cups per day, is POSSIBLY UNSAFE. High amounts of black tea can cause side effects due to the caffeine in black tea. These side effects can range from mild to serious and include headache, nervousness, sleep problems, vomiting, diarrhea, irritability, irregular heartbeat, tremor, heartburn, dizziness, ringing in the ears, convulsions, and confusion. Also, people who drink black tea or other caffeinated beverages all the time, especially in large amounts, can develop psychological dependence.

Drinking very high amounts of black tea containing more than 10 grams of caffeine is LIKELY UNSAFE. Doses of black tea this high might cause death or other severe side effects.

Caffeine is PROBABLY SAFE in children in amounts commonly found in foods.

Special precautions & warnings:

Children: Black tea is POSSIBLY SAFE when taken by mouth by children in amounts commonly found in foods.

Pregnancy and breast-feeding: If you are pregnant or breast-feeding, drinking black tea in small amounts is POSSIBLY SAFE. Do not drink more than 3 cups a day of black tea. This amount of tea provides about 200 mg of caffeine. Consuming more than this amount during pregnancy is POSSIBLY UNSAFE and has been linked to an increased risk of miscarriage, increased risk of sudden infant death syndrome (SIDS), and other negative effects, including symptoms of caffeine withdrawal in newborns and lower birth weight.

If you are breast-feeding, drinking more than 3 cups a day of black tea is POSSIBLY UNSAFE and might cause your baby to become more irritable and have more bowel movements.

Anemia: Drinking black tea may make anemia worse in people with iron deficiency.

Anxiety disorders: The caffeine in black tea might make these conditions worse.

Bleeding disorders: There is some reason to believe that the caffeine in black tea might slow blood clotting, though this hasn’t been shown in people. Use caffeine cautiously if you have a bleeding disorder.

Heart problems: Caffeine in black tea can cause irregular heartbeat in certain people. If you have a heart condition, use caffeine with caution.

Diabetes: The caffeine in black tea might affect blood sugar. Use black tea with caution if you have diabetes.

Diarrhea: Black tea contains caffeine. The caffeine in black tea, especially when taken in large amounts, can worsen diarrhea.

Seizures: Black tea contains caffeine. There is a concern that high doses of caffeine might cause seizures or decrease the effects of drugs used to prevent seizures. If you have ever had a seizure, don’t use high doses of caffeine or caffeine-containing supplements such as black tea.

Glaucoma: Drinking caffeinated black tea increases the pressure inside the eye. The increase occurs within 30 minutes and lasts for at least 90 minutes.

Hormone-sensitive condition such as breast cancer, uterine cancer, ovarian cancer, endometriosis, or uterine fibroids: Black tea might act like estrogen. If you have any condition that might be made worse by exposure to estrogen, don’t use black tea.

High blood pressure: The caffeine in black tea might increase blood pressure in people with high blood pressure. However, this doesn't seem to occur in people who drink black tea or other caffeinated products regularly.

Irritable bowel syndrome (IBS): Black tea contains caffeine. The caffeine in black tea, especially when taken in large amounts, can worsen diarrhea and might worsen symptoms of IBS.

Brittle bones (osteoporosis): Drinking caffeinated black tea can increase the amount of calcium that is flushed out in the urine. This might weaken bones. Don’t drink more than 300 mg of caffeine per day (approximately 2-3 cups of black tea). Taking extra calcium may help to make up for calcium losses. Older women who have a genetic condition that affects the way they use vitamin D, should use caffeine with caution.

Overactive bladder: The caffeine in black tea might increase the risk of developing an overactive bladder. Also, black tea might increase symptoms in people who already have an overactive bladder. Black tea should be used with caution in these people.

Are there interactions with medications?

Return to top

Moderate

Be cautious with this combination.

Adenosine (Adenocard)
Black tea contains caffeine. The caffeine in black tea might block the effects of adenosine (Adenocard). Adenosine (Adenocard) is often used by doctors to do a test on the heart. This test is called a cardiac stress test. Stop drinking black tea or other caffeine-containing products at least 24 hours before a cardiac stress test.

Antibiotics (Quinolone antibiotics)
The body breaks down caffeine to get rid of it. Some antibiotics might decrease how quickly the body breaks down caffeine. Taking these antibiotics along with black tea can increase the risk of side effects including jitteriness, headache, increased heart rate, and other side effects.

Some antibiotics that decrease how quickly the body breaks down caffeine include ciprofloxacin (Cipro), enoxacin (Penetrex), norfloxacin (Chibroxin, Noroxin), sparfloxacin (Zagam), trovafloxacin (Trovan), and grepafloxacin (Raxar).

Benzodiazepines
Benzodiazepines are drugs that have calming effects. Black tea contains caffeine. Caffeine is a stimulant. Taking black tea along with benzodiazepines might block the calming effects of can benzodiazepines. Some benzodiazepines include alprazolam (Xanax), clonazepam (Klonopin), diazepam (Valium), lorazepam (Ativan), and others.

Carbamazepine (Tegretol)
Carbamazepine is a drug used to treat seizures. Caffeine in black tea can decrease the effects of carbamazepine. Taking black tea with carbamazepine might decrease the effects of carbamazepine and increase the risk of seizures in some people.

Cimetidine (Tagamet)
Black tea contains caffeine. The body breaks down caffeine to get rid of it. Cimetidine (Tagamet) can decrease how quickly your body breaks down caffeine. Taking cimetidine (Tagamet) along with black tea might increase the chance of caffeine side effects including jitteriness, headache, fast heartbeat, and others.

Clozapine (Clozaril)
The body breaks down clozapine (Clozaril) to get rid of it. The caffeine in black tea seems to decrease how quickly the body breaks down clozapine (Clozaril). Taking black tea along with clozapine (Clozaril) can increase the effects and side effects of clozapine (Clozaril).

Dipyridamole (Persantine)
Black tea contains caffeine. The caffeine in black tea might block the affects of dipyridamole (Persantine). Dipyridamole (Persantine) is often used by doctors to do a test on the heart. This test is called a cardiac stress test. Stop drinking black tea or other caffeine-containing products at least 24 hours before a cardiac stress test.

Disulfiram (Antabuse)
The body breaks down caffeine to get rid of it. Disulfiram (Antabuse) can decrease how quickly the body gets rid of caffeine. Taking black tea (which contains caffeine) along with disulfiram (Antabuse) might increase the effects and side effects of caffeine including jitteriness, hyperactivity, irritability, and others.

Ephedrine
Stimulant drugs speed up the nervous system. Black tea contains caffeine. Caffeine and ephedrine are both stimulant drugs. Taking black tea along with ephedrine might cause too much stimulation and sometimes serious side effects and heart problems. Do not take caffeine containing products and ephedrine at the same time.

Estrogens
The body breaks down the caffeine in black tea to get rid of it. Estrogens can decrease how quickly the body breaks down caffeine. Taking estrogen pills and drinking black tea can cause jitteriness, headache, fast heartbeat, and other side effects. If you take estrogen pills, limit your caffeine intake.

Some estrogen pills include conjugated equine estrogens (Premarin), ethinyl estradiol, estradiol, and others.

Ethosuximide
Ethosuximide is a drug used to treat seizures. Caffeine in black tea can decrease the effects of ethosuximide. Taking black tea with ethosuximide might decrease the effects of ethosuximide and increase the risk of seizures in some people.

Felbamate
Felbamate is a drug used to treat seizures. Caffeine in black tea can decrease the effects of felbamate. Taking black tea with felbamate might decrease the effects of felbamate and increase the risk of seizures in some people.

Flutamide (Eulexin)
The body breaks down flutamide (Eulexin) to get rid of it. Caffeine in black tea might decrease how quickly the body gets rid of flutamide. This could cause flutamide to stay in the body too long and increase the risk of side effects.

Fluvoxamine (Luvox)
The body breaks down the caffeine in black tea to get rid of it. Fluvoxamine (Luvox) can decrease how quickly the body breaks down caffeine. Taking caffeine along with fluvoxamine (Luvox) might cause too much caffeine in the body, and increase the effects and side effects of caffeine.

Lithium
Your body naturally gets rid of lithium. The caffeine in black tea can increase how quickly your body gets rid of lithium. If you take products that contain caffeine and you take lithium, stop taking caffeine products slowly. Stopping caffeine too quickly can increase the side effects of lithium.

Medications for asthma (Beta-adrenergic agonists)
Black tea contains caffeine. Caffeine can stimulate the heart. Some medications for asthma can also stimulate the heart. Taking caffeine with some medications for asthma might cause too much stimulation and cause heart problems.

Some medications for asthma include albuterol (Proventil, Ventolin, Volmax), metaproterenol (Alupent), terbutaline (Bricanyl, Brethine), and isoproterenol (Isuprel).

Medications for depression (MAOIs)
The caffeine in black tea can stimulate the body. Some medications used for depression can also stimulate the body. Drinking black tea and taking some medications for depression might cause too much stimulation of the body and serious side effects including fast heartbeat, high blood pressure, nervousness, and others.

Some of these medications used for depression include phenelzine (Nardil), tranylcypromine (Parnate), and others.

Medications that change the liver (Cytochrome P450 1A2 (CYP1A2) inhibitors)
Black tea contains caffeine. Caffeine is broken down by the liver. Some medications decrease how well the liver breaks down other medications. These medications that change the liver might decrease how fast caffeine in black tea is broken down in the body. This might increase the effects and side effects of caffeine in black tea. Some medications that change the liver include cimetidine (Tagamet), ciprofloxacin (Cipro), fluvoxamine (Luvox), and others.

Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs)
Black tea contains caffeine. Caffeine might slow blood clotting. Taking black tea along with medications that also slow clotting might increase the chances of bruising and bleeding.

Some medications that slow blood clotting include aspirin, clopidogrel (Plavix), diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.

Nicotine
Black tea contains caffeine. Caffeine can stimulate the heart. Nicotine can also stimulate the heart. Taking caffeine with nicotine might cause too much stimulation and cause heart problems, such as increased heart rate or blood pressure.

Pentobarbital (Nembutal)
The stimulant effects of the caffeine in black tea can block the sleep-producing effects of pentobarbital.

Phenobarbital
Phenobarbital is a drug used to treat seizures. Caffeine in black tea can decrease the effects of phenobarbital. Taking black tea with phenobarbital might decrease the effects of phenobarbital and increase the risk of seizures in some people.

Phenylpropanolamine
The caffeine in black tea can stimulate the body. Phenylpropanolamine can also stimulate the body. Taking caffeine and phenylpropanolamine together might cause too much stimulation and increase heartbeat, blood pressure, and cause nervousness.

Phenytoin
Phenytoin is a drug used to treat seizures. Caffeine in black tea can decrease the effects of phenytoin. Taking black tea with phenytoin might decrease the effects of phenytoin and increase the risk of seizures in some people.

Riluzole (Rilutek)
The body breaks down riluzole (Rilutek) to get rid of it. Drinking black tea can decrease how quickly the body breaks down riluzole (Rilutek) and increase the effects and side effects of riluzole.

Stimulant drugs
Stimulant drugs speed up the nervous system. By speeding up the nervous system, stimulant medications can make you feel jittery and speed up your heartbeat. The caffeine in black tea can also speed up the nervous system. Drinking black tea along with stimulant drugs might cause serious problems including increased heart rate and high blood pressure. Avoid taking stimulant drugs along with black tea.

Some stimulant drugs include diethylpropion (Tenuate), epinephrine, phentermine (Ionamin), pseudoephedrine (Sudafed), and many others.

Theophylline
Black tea contains caffeine. Caffeine works similarly to theophylline. Caffeine can also decrease how quickly the body gets rid of theophylline. This might cause increased effects and side effects of theophylline.

Valproate
Valproate is a drug used to treat seizures. Caffeine in black tea can decrease the effects of valproate. Taking black tea with valproate might decrease the effects of valproate and increase the risk of seizures in some people.

Verapamil (Calan, Covera, Isoptin, Verelan)
The body breaks down the caffeine in black tea to get rid of it. Verapamil (Calan, Covera, Isoptin, Verelan) can decrease how quickly the body gets rid of caffeine. Drinking black tea and taking verapamil (Calan, Covera, Isoptin, Verelan) can increase the risk of side effects for caffeine including jitteriness, headache, and an increased heartbeat.

Warfarin (Coumadin)
Warfarin (Coumadin) is used to slow blood clotting. Large amounts of black tea might decrease how well warfarin (Coumadin) slows blood clotting. Decreasing how well warfarin (Coumadin) slows blood clotting might increase the risk of clotting. It is unclear why this interaction might occur. Be sure to have your blood checked regularly. The dose of your warfarin (Coumadin) might need to be changed.

Water pills (Diuretic drugs)
Black tea contains caffeine. Caffeine, especially in excessive amounts, can reduce potassium in the body. "Water pills" can also decrease potassium in the body. Taking caffeine-containing products along with "water pills" might decrease potassium in the body too much.

Some "water pills" that can decrease potassium include chlorothiazide (Diuril), chlorthalidone (Thalitone), furosemide (Lasix), hydrochlorothiazide (HCTZ, HydroDIURIL, Microzide), and others.

Minor

Be watchful with this combination.

Alcohol
Black tea contains caffeine. The body breaks down the caffeine in black tea to get rid of it. Alcohol can decrease how quickly the body breaks down caffeine. Taking black tea along with alcohol might cause too much caffeine in the bloodstream and caffeine side effects including jitteriness, headache, and fast heartbeat.

Birth control pills (Contraceptive drugs)
Black tea contains caffeine. The body breaks down caffeine to get rid of it. Birth control pills can decrease how quickly the body breaks down caffeine. Taking black tea along with birth control pills might cause jitteriness, headache, fast heartbeat, and other side effects.

Some birth control pills include ethinyl estradiol and levonorgestrel (Triphasil), ethinyl estradiol and norethindrone (Ortho-Novum 1/35, Ortho-Novum 7/7/7), and others.

Fluconazole (Diflucan)
Black tea contains caffeine. The body breaks down caffeine to get rid of it. Fluconazole (Diflucan) might decrease how quickly the body gets rid of caffeine. This could cause caffeine to stay in the body too long and increase the risk of side effects such as nervousness, anxiety, and insomnia.

Medications for depression (Tricyclic antidepressants)
Black tea contains chemicals called tannins. Tannins can bind to many medications and decrease how much medicine the body absorbs. To avoid this interaction, avoid black tea 1 hour before and 2 hours after taking medications for depression called tricyclic antidepressants.

Some medications for depression include amitriptyline (Elavil) or imipramine (Tofranil, Janimine).

Medications for diabetes (Antidiabetes drugs)
Black tea contains caffeine. Caffeine might increase blood sugar. Diabetes medications are used to lower blood sugar. By increasing blood sugar, black tea might decrease the effectiveness of diabetes medications. Monitor your blood sugar closely. The dose of your diabetes medication might need to be changed.

Some medications used for diabetes include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, pioglitazone (Actos), rosiglitazone (Avandia), chlorpropamide (Diabinese), glipizide (Glucotrol), tolbutamide (Orinase), and others.

METFORMIN (Glucophage)
Black tea contains caffeine. The body breaks down caffeine to get rid of it. Metformin (Glucophage) can decrease how quickly the body breaks down caffeine. Taking black tea along with metformin might cause too much caffeine in the body, and increase the effects and side effects of caffeine.

Methoxsalen (Oxsoralen)
Black tea contains caffeine. The body breaks down caffeine to get rid of it. Methoxsalen (Oxsoralen) can decrease how quickly the body breaks down caffeine. Taking caffeine along with methoxsalen might cause too much caffeine in the body, and increase the effects and side effects of caffeine.

Mexiletine (Mexitil)
Black tea contains caffeine. The body breaks down caffeine to get rid of it. Mexiletine (Mexitil) can decrease how quickly the body breaks down caffeine. Taking Mexiletine (Mexitil) along with black tea might increase the caffeine effects and side effects of black tea.

Phenothiazines
Black tea contains chemicals called tannins. Tannins can bind to many medications and decrease how much medicine the body absorbs. To avoid this interaction, avoid black tea one hour before and two hours after taking phenothiazine medications.

Some phenothiazine medications include fluphenazine (Permitil, Prolixin), chlorpromazine (Thorazine), haloperidol (Haldol), prochlorperazine (Compazine), thioridazine (Mellaril), and trifluoperazine (Stelazine).

Terbinafine (Lamisil)
The body breaks down the caffeine in black tea to get rid of it. Terbinafine (Lamisil) can decrease how quickly the body gets rid of caffeine and increase the risk of side effects including jitteriness, headache, increased heartbeat, and other effects.

Tiagabine
Black tea contains caffeine. Taking caffeine over a long time period along with tiagabine can increase the amount of tiagabine in the body. This might increase the side effects of tiagabine.

Ticlopidine (Ticlid)
The body breaks down the caffeine in black tea to get rid of it. Ticlopidine (Ticlid) can decrease how quickly the body gets rid of caffeine. Taking black tea along with ticlopidine might increase the effects and side effects of caffeine, including jitteriness, hyperactivity, irritability, and others.

Are there interactions with herbs and supplements?

Return to top
Bitter orange
Using bitter orange along with other products that contain caffeine, such as black tea, can increase blood pressure and heart rate in otherwise healthy adults with normal blood pressure. This could increase the risk of serious heart problems.

Caffeine-containing herbs and supplements
Black tea contains caffeine. Using it along with other herbs and supplements that contain caffeine might increase the risk of caffeine side effects. Natural products that contain caffeine include coffee, black tea, green tea, oolong tea, guarana, mate, and others.

Calcium
High caffeine intake from foods and beverages, including black tea, flushes calcium out of the body in the urine.

Cordyceps
Black tea contains caffeine. The body breaks down caffeine to get rid of it. Cordyceps might increase how quickly the body gets rid of caffeine. This might decrease the effects of caffeine.

Creatine
There is some concern that combining caffeine, an ingredient in black tea, with ephedra and creatine might increase the risk of serious harmful effects. There is a report of stroke in an athlete who consumed 6 grams of creatine monohydrate, 400-600 mg of caffeine, 40-60 mg of ephedra, and a variety of other supplements daily for 6 weeks. Caffeine might also decrease whatever benefit creatine might have on athletic performance.

Danshen
Black tea contains caffeine. The body breaks down caffeine to get rid of it. Danshen can decrease how quickly the body gets rid of caffeine. Drinking black tea and taking danshen might increase the risk of side effects for caffeine, including jitteriness, headache, and an increased heartbeat.

Echinacea
Black tea contains caffeine. The body breaks down caffeine to get rid of it. Echinacea can decrease how quickly the body gets rid of caffeine. Drinking black tea and taking echinacea might increase the risk of side effects for caffeine, including jitteriness, headache, and an increased heartbeat.

Ephedra (Ma huang)
Ephedra and black tea are both stimulants. They speed up the central nervous system. Using them together might speed it up too much, increasing the risk of high blood pressure, heart attack, stroke, seizures, and death. Don't take black tea with ephedra or other stimulants.

Folic acid
Black tea might reduce the amount of folate that the body can absorb and use.

Herbs and supplements that might slow blood clotting
Black tea might slow blood clotting. Using it along with other herbs and supplements that might also slow blood clotting could increase the risk of bruising and bleeding in some people. Some of these herbs include angelica, clove, danshen, garlic, ginger, ginkgo, Panax ginseng, and others.

Iron
Black tea might interfere with the body's ability to absorb iron. This probably isn't a problem for most people, unless they are iron-deficient. If this is the case, drink tea between meals rather than with meals to lessen this interaction.

Kudzu
Black tea contains caffeine. The body breaks down caffeine to get rid of it. Kudzu can decrease how quickly the body gets rid of caffeine. Drinking black tea and taking kudzu might increase the risk of side effects for caffeine, including jitteriness, headache, and an increased heartbeat.

Magnesium
Drinking large amounts of black tea can increase the amount of magnesium that is flushed out in the urine.

Melatonin
Black tea contains caffeine. Taking caffeine and melatonin together can increase melatonin levels. Caffeine can also increase natural melatonin levels in healthy individuals.

Red clover
Black tea contains caffeine. The body breaks down caffeine to get rid of it. Chemicals in red clover can decrease how quickly the body gets rid of caffeine. Drinking black tea and taking red clover might increase the risk of side effects for caffeine, including jitteriness, headache, and an increased heartbeat.

Are there interactions with foods?

Return to top
Iron
Black tea might interfere with the body's ability to absorb iron. This probably isn't a problem for most people, unless they are iron-deficient. If this is the case, drink tea between meals rather than with meals to lessen this interaction.

Milk
Adding milk to black tea appears to reduce some of the heart health benefits of drinking tea. Milk might bind with the antioxidants in tea and keep them from being absorbed. However, not all research confirms this. More evidence is needed to determine just how important this interaction, if any, might be.

What dose is used?

Return to top
An 8-ounce serving of black tea provides from 40-120 mg of caffeine, the active ingredient.

The following doses have been studied in scientific research:

BY MOUTH:
  • For headache or improving mental alertness: a typical dose is up to 250 mg of caffeine (several cups of black tea) per day.
  • For reducing the risk of heart attack and kidney stones: a dose of at least one cup per day.
  • For preventing "hardening of the arteries" (atherosclerosis), 125-500 mL (1-4 cups) of brewed black tea daily.
  • For preventing Parkinson's disease: men drinking 421-2716 mg of total caffeine (approximately 5-33 cups of black tea) daily have the lowest risk of developing Parkinson's disease, when compared to other men. However, men who drink as little as 124-208 mg of caffeine (approximately 1-3 cups of black tea) daily also have a significantly lower chance of developing Parkinson's disease. In women, moderate caffeine intake (1-4 cups of black tea) per day seems to be best.

Other names

Return to top
Black Leaf Tea, Camellia sinensis, Camellia thea, Camellia theifera, Chinese Tea, English Tea, Feuille de Thé Noir, Té Negro, Tea, Thé Anglais, Thé Noir, Thea bohea, Thea sinensis, Thea viridis, Theaflavin, Théaflavine.

Methodology

Return to top
To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.methodology (http://www.nlm.nih.gov/medlineplus/druginfo/natural/methodology.html).

References

Return to top
To see all references for the Black tea page, please go to http://www.nlm.nih.gov/medlineplus/druginfo/natural/997.html.

  1. Smits, P., Corstens, F. H., Aengevaeren, W. R., Wackers, F. J., and Thien, T. False-negative dipyridamole-thallium-201 myocardial imaging after caffeine infusion. J Nucl.Med. 1991;32:1538-1541. View abstract.
  2. Alemdaroglu, N. C., Dietz, U., Wolffram, S., Spahn-Langguth, H., and Langguth, P. Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability. Biopharm.Drug Dispos. 2008;29:335-348. View abstract.
  3. Izzo, A. A. and Ernst, E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009;69:1777-1798. View abstract.
  4. Cook, D. G., Peacock, J. L., Feyerabend, C., Carey, I. M., Jarvis, M. J., Anderson, H. R., and Bland, J. M. Relation of caffeine intake and blood caffeine concentrations during pregnancy to fetal growth: prospective population based study. BMJ 11-30-1996;313:1358-1362. View abstract.
  5. Jeppesen, U., Loft, S., Poulsen, H. E., and Brsen, K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-222. View abstract.
  6. Dlugosz, L., Belanger, K., Hellenbrand, K., Holford, T. R., Leaderer, B., and Bracken, M. B. Maternal caffeine consumption and spontaneous abortion: a prospective cohort study. Epidemiology 1996;7:250-255. View abstract.
  7. Srisuphan, W. and Bracken, M. B. Caffeine consumption during pregnancy and association with late spontaneous abortion. Am.J Obstet.Gynecol. 1986;154:14-20. View abstract.
  8. Martin, T. R. and Bracken, M. B. The association between low birth weight and caffeine consumption during pregnancy. Am.J.Epidemiol. 1987;126:813-821. View abstract.
  9. Caan, B. J. and Goldhaber, M. K. Caffeinated beverages and low birthweight: a case-control study. Am.J.Public Health 1989;79:1299-1300. View abstract.
  10. Smits, P., Lenders, J. W., and Thien, T. Caffeine and theophylline attenuate adenosine-induced vasodilation in humans. Clin.Pharmacol.Ther. 1990;48:410-418. View abstract.
  1. Perera, V., Gross, A. S., and McLachlan, A. J. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. Biomed.Chromatogr. 2010;24:1136-1144. View abstract.
  2. Fenster, L., Eskenazi, B., Windham, G. C., and Swan, S. H. Caffeine consumption during pregnancy and spontaneous abortion. Epidemiology 1991;2:168-174. View abstract.
  3. Banko, L. T., Haq, S. A., Rainaldi, D. A., Klem, I., Siegler, J., Fogel, J., Sacchi, T. J., and Heitner, J. F. Incidence of caffeine in serum of patients undergoing dipyridamole myocardial perfusion stress test by an intensive versus routine caffeine history screening. Am.J Cardiol. 5-15-2010;105:1474-1479. View abstract.
  4. Mevcha, A., Gulur, D. M., and Gillatt, D. Diagnosing urological disorders in ageing men. Practitioner 2010;254:25-9, 2. View abstract.
  5. Fenster, L., Eskenazi, B., Windham, G. C., and Swan, S. H. Caffeine consumption during pregnancy and fetal growth. Am.J.Public Health 1991;81:458-461. View abstract.
  6. Hashim, H. and Al, Mousa R. Management of fluid intake in patients with overactive bladder. Curr.Urol.Rep. 2009;10:428-433. View abstract.
  7. Barr, H. M. and Streissguth, A. P. Caffeine use during pregnancy and child outcome: a 7-year prospective study. Neurotoxicol.Teratol. 1991;13:441-448. View abstract.
  8. Clausson, B., Granath, F., Ekbom, A., Lundgren, S., Nordmark, A., Signorello, L. B., and Cnattingius, S. Effect of caffeine exposure during pregnancy on birth weight and gestational age. Am.J.Epidemiol. 3-1-2002;155:429-436. View abstract.
  9. Cnattingius, S., Signorello, L. B., Anneren, G., Clausson, B., Ekbom, A., Ljunger, E., Blot, W. J., McLaughlin, J. K., Petersson, G., Rane, A., and Granath, F. Caffeine intake and the risk of first-trimester spontaneous abortion. N.Engl.J.Med. 12-21-2000;343:1839-1845. View abstract.
  10. Princen, H. M., van, Duyvenvoorde W., Buytenhek, R., Blonk, C., Tijburg, L. B., Langius, J. A., Meinders, A. E., and Pijl, H. No effect of consumption of green and black tea on plasma lipid and antioxidant levels and on LDL oxidation in smokers. Arterioscler.Thromb.Vasc.Biol. 1998;18:833-841. View abstract.
  11. Tavani, A., Pregnolato, A., La, Vecchia C., Negri, E., Talamini, R., and Franceschi, S. Coffee and tea intake and risk of cancers of the colon and rectum: a study of 3,530 cases and 7,057 controls. Int.J Cancer 10-9-1997;73:193-197. View abstract.
  12. Bingham, S. A., Vorster, H., Jerling, J. C., Magee, E., Mulligan, A., Runswick, S. A., and Cummings, J. H. Effect of black tea drinking on blood lipids, blood pressure and aspects of bowel habit. Br J Nutr 1997;78:41-55. View abstract.
  13. Zheng, W., Doyle, T. J., Kushi, L. H., Sellers, T. A., Hong, C. P., and Folsom, A. R. Tea consumption and cancer incidence in a prospective cohort study of postmenopausal women. Am.J Epidemiol. 7-15-1996;144:175-182. View abstract.
  14. Pincomb, G. A., Lovallo, W. R., McKey, B. S., Sung, B. H., Passey, R. B., Everson, S. A., and Wilson, M. F. Acute blood pressure elevations with caffeine in men with borderline systemic hypertension. Am.J Cardiol. 2-1-1996;77:270-274. View abstract.
  15. Goldbohm, R. A., Hertog, M. G., Brants, H. A., van Poppel, G., and Van den Brandt, P. A. Consumption of black tea and cancer risk: a prospective cohort study. J.Natl.Cancer Inst. 1-17-1996;88:93-100. View abstract.
  16. Zatonski, W. A., Boyle, P., Przewozniak, K., Maisonneuve, P., Drosik, K., and Walker, A. M. Cigarette smoking, alcohol, tea and coffee consumption and pancreas cancer risk: a case-control study from Opole, Poland. Int.J Cancer 2-20-1993;53:601-607. View abstract.
  17. Smits, P., Temme, L., and Thien, T. The cardiovascular interaction between caffeine and nicotine in humans. Clin Pharmacol Ther 1993;54:194-204. View abstract.
  18. Sung, B. H., Whitsett, T. L., Lovallo, W. R., al'Absi, M., Pincomb, G. A., and Wilson, M. F. Prolonged increase in blood pressure by a single oral dose of caffeine in mildly hypertensive men. Am.J Hypertens. 1994;7:755-758. View abstract.
  19. Baron, J. A., Gerhardsson, de, V, and Ekbom, A. Coffee, tea, tobacco, and cancer of the large bowel. Cancer Epidemiol.Biomarkers Prev. 1994;3:565-570. View abstract.
  20. Conrad, K. A., Blanchard, J., and Trang, J. M. Cardiovascular effects of caffeine in elderly men. J Am.Geriatr.Soc. 1982;30:267-272. View abstract.
  21. Dobmeyer, D. J., Stine, R. A., Leier, C. V., Greenberg, R., and Schaal, S. F. The arrhythmogenic effects of caffeine in human beings. N.Engl.J.Med. 4-7-1983;308:814-816. View abstract.
  22. Heilbrun, L. K., Nomura, A., and Stemmermann, G. N. Black tea consumption and cancer risk: a prospective study. Br.J.Cancer 1986;54:677-683. View abstract.
  23. Kinlen, L. J., Willows, A. N., Goldblatt, P., and Yudkin, J. Tea consumption and cancer. Br.J.Cancer 1988;58:397-401. View abstract.
  24. Van Dusseldorp, M., Smits, P., Thien, T., and Katan, M. B. Effect of decaffeinated versus regular coffee on blood pressure. A 12-week, double-blind trial. Hypertension 1989;14:563-569. View abstract.
  25. Mukamal, K. J., MacDermott, K., Vinson, J. A., Oyama, N., Manning, W. J., and Mittleman, M. A. A 6-month randomized pilot study of black tea and cardiovascular risk factors. Am Heart J 2007;154:724-726. View abstract.
  26. Mackenzie, T., Leary, L., and Brooks, W. B. The effect of an extract of green and black tea on glucose control in adults with type 2 diabetes mellitus: double-blind randomized study. Metabolism 2007;56:1340-1344. View abstract.
  27. Opala, T., Rzymski, P., Pischel, I., Wilczak, M., and Wozniak, J. Efficacy of 12 weeks supplementation of a botanical extract-based weight loss formula on body weight, body composition and blood chemistry in healthy, overweight subjects--a randomised double-blind placebo-controlled clinical trial. Eur J Med Res 8-30-2006;11:343-350. View abstract.
  28. Steptoe, A., Gibson, E. L., Vuononvirta, R., Williams, E. D., Hamer, M., Rycroft, J. A., Erusalimsky, J. D., and Wardle, J. The effects of tea on psychophysiological stress responsivity and post-stress recovery: a randomised double-blind trial. Psychopharmacology (Berl) 2007;190:81-89. View abstract.
  29. Steptoe, A., Gibson, E. L., Vuononvirta, R., Hamer, M., Wardle, J., Rycroft, J. A., Martin, J. F., and Erusalimsky, J. D. The effects of chronic tea intake on platelet activation and inflammation: a double-blind placebo controlled trial. Atherosclerosis 2007;193:277-282. View abstract.
  30. Gardner, E. J., Ruxton, C. H., and Leeds, A. R. Black tea--helpful or harmful? A review of the evidence. Eur J Clin Nutr 2007;61:3-18. View abstract.
  31. Sun, C. L., Yuan, J. M., Koh, W. P., and Yu, M. C. Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Carcinogenesis 2006;27:1301-1309. View abstract.
  32. Halder, A., Raychowdhury, R., Ghosh, A., and De, M. Black tea (Camellia sinensis) as a chemopreventive agent in oral precancerous lesions. J.Environ.Pathol.Toxicol.Oncol. 2005;24:141-144. View abstract.
  33. Davies, M. J., Judd, J. T., Baer, D. J., Clevidence, B. A., Paul, D. R., Edwards, A. J., Wiseman, S. A., Muesing, R. A., and Chen, S. C. Black tea consumption reduces total and LDL cholesterol in mildly hypercholesterolemic adults. J.Nutr. 2003;133:3298S-3302S. View abstract.
  34. Stensvold, I., Tverdal, A., Solvoll, K., and Foss, O. P. Tea consumption. relationship to cholesterol, blood pressure, and coronary and total mortality. Prev.Med. 1992;21:546-553. View abstract.
  35. Hakim, I. A., Alsaif, M. A., Alduwaihy, M., Al-Rubeaan, K., Al-Nuaim, A. R., and Al-Attas, O. S. Tea consumption and the prevalence of coronary heart disease in Saudi adults: results from a Saudi national study. Prev.Med 2003;36:64-70. View abstract.
  36. Cerhan, J. R., Putnam, S. D., Bianchi, G. D., Parker, A. S., Lynch, C. F., and Cantor, K. P. Tea consumption and risk of cancer of the colon and rectum. Nutr.Cancer 2001;41(1-2):33-40. View abstract.
  37. Hodgson, J. M., Puddey, I. B., Burke, V., Watts, G. F., and Beilin, L. J. Regular ingestion of black tea improves brachial artery vasodilator function. Clin.Sci (Lond) 2002;102:195-201. View abstract.
  38. Arts, I. C., Hollman, P. C., Feskens, E. J., Bueno de Mesquita, H. B., and Kromhout, D. Catechin intake might explain the inverse relation between tea consumption and ischemic heart disease: the Zutphen Elderly Study. Am.J.Clin Nutr. 2001;74:227-232. View abstract.
  39. Arya, L. A., Myers, D. L., and Jackson, N. D. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstet.Gynecol. 2000;96:85-89. View abstract.
  40. Woodward, M. and Tunstall-Pedoe, H. Coffee and tea consumption in the Scottish Heart Health Study follow up: conflicting relations with coronary risk factors, coronary disease, and all cause mortality. J.Epidemiol.Community Health 1999;53:481-487. View abstract.
  41. Chow, W. H., Swanson, C. A., Lissowska, J., Groves, F. D., Sobin, L. H., Nasierowska-Guttmejer, A., Radziszewski, J., Regula, J., Hsing, A. W., Jagannatha, S., Zatonski, W., and Blot, W. J. Risk of stomach cancer in relation to consumption of cigarettes, alcohol, tea and coffee in Warsaw, Poland. Int.J.Cancer 6-11-1999;81:871-876. View abstract.
  42. Uhde TW, Boulenger JP, Jimerson DC, Post RM. Caffeine: relationship to human anxiety, plasma MHPG and cortisol. Psychopharmacol Bull 1984;20:426-30. View abstract.
  43. Charney DS, Heninger GR, Jatlow PI. Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 1985;42:233-43. View abstract.
  44. Boulenger JP, Uhde TW. Caffeine consumption and anxiety: preliminary results of a survey comparing patients with anxiety disorders and normal controls. Psychopharmacol Bull 1982;18:53-7. View abstract.
  45. Ford RP, Schluter PJ, Mitchell EA, et al. Heavy caffeine intake in pregnancy and sudden infant death syndrome. New Zealand Cot Death Study Group. Arch Dis Child 1998;78:9-13. View abstract.
  46. Fortier I, Marcoux S, Beaulac-Baillargeon L. Relation of caffeine intake during pregnancy to intrauterine growth retardation and preterm birth. Am J Epidemiol 1993;137:931-40. View abstract.
  47. Weathersbee PS, Olsen LK, Lodge JR. Caffeine and pregnancy. A retrospective survey. Postgrad Med 1977;62:64-9. View abstract.
  48. Jia H, Xu A, Yuan J, et al. Experimental study on cytochrome P450 enzymes after receiving ferment powder caterpillar fungus. Zhongguo Zhong Yao Za Zhi 2009;34:2079-82. View abstract.
  49. Jonkman JH, Sollie FA, Sauter R, Steinijans VW. The influence of caffeine on the steady-state pharmacokinetics of theophylline. Clin Pharmacol Ther 1991;49:248-55. View abstract.
  50. Joeres R, Richter E. Mexiletine and caffeine elimination. N Engl J Med 1987;317:117. View abstract.
  51. de Alarcon PA, Donovan ME, Forbes GB, et al. Iron absorption in the thalassemia syndromes and its inhibition by tea. N Engl J Med 1979;300:5-8. View abstract.
  52. Zelenitsky SA, Norman A, Nix DE. The effects of fluconazole on the pharmacokinetics of caffeine in young and elderly subjects. J Infect Dis Pharmacother 1995;1:1-11.
  53. Smits P, Straatman C, Pijpers E, Thien T. Dose-dependent inhibition of the hemodynamic response to dipyridamole by caffeine. Clin Pharmacol Ther 1991;50:529-37. View abstract.
  54. Jenkins J, Williams D, Deng Y, et al. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. Eur J Clin Pharmacol 2010;66:67-76. View abstract.
  55. Filimonova AA, Ziganshina LE, Ziganshin AU, Chichirov AA. On the possibility of patient phenotyping on the basis of cytochrome p-450 1A2 isoenzyme activity using caffeine as the test substrate. Eksp Klin Farmakol 2009;72:61-5. View abstract.
  56. Turpault S, Brian W, Van Horn R, et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6, and 3A. Br J Clin Pharmacol 2009;68:928-35. View abstract.
  57. Mills BM, Zaya MJ, Walters RR, et al. Current cytochrome P450 phenotyping methods applied to metabolic drug -drug interaction prediction in dogs. Drug Metab Dispos 2010;38:396-404. View abstract.
  58. Chien CF, Wu YT, Lee WC, et al. Herb-drug interaction of Andrographis paniculata extract and andrographolide on the pharmacokinetics of theophylline in rats. Chem Biol Interact 2010;184:458-65. View abstract.
  59. Suzuki S, Murayama Y, Sugiyama E, et al. Estimating pediatric doses of drugs metabolized by cytochrome P450 (CYP) isozymes, based on physiological liver development and serum protein levels. Yakugaku Zasshi 2010;130:613-20. View abstract.
  60. Chen Y, Kang Z, Yan J, et al. Liu wei di huang wan, a well-known traditional Chinese medicine induces CYP1A2 while suppressing CYP2A6 and N-acetyltransferase 2 acivities in man. J Ethnopharmacol 2010;132:213-8. View abstract.
  61. Goh BC, Reddy NJ, Dandamudi UB, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 2010;88:652-9. View abstract.
  62. Kjaerstad MB, Nielsen F, Nohr-Jensen L, et al. Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women. Eur J Clin Pharmacol 2010;66:1189-97. View abstract.
  63. Kot M, Daniel WA. Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacol Rep 2008;60:789-97. View abstract.
  64. Mattila MJ, Vainio P, Nurminen ML, et al. Midazolam 12 mg is moderately counteracted by 250 mg caffeine in man. Int J Clin Pharmacol Ther 2000;38:581-7. View abstract.
  65. Mattila ME, Mattila MJ, Nuotto E. Caffeine moderately antagonizes the effects of triazolam and zopiclone on the psychomotor performance of healthy subjects. Pharmacol Toxicol 1992;70:286-9. View abstract.
  66. Mattila MJ, Nuotto E. Caffeine and theophylline counteract diazepam effects in man. Med Biol 1983;61:337-43. View abstract.
  67. Mattila MJ, Palva E, Savolainen K. Caffeine antagonizes diazepam effects in man. Med Biol 1982;60:121-3. View abstract.
  68. File SE, Bond AJ, Lister RG. Interaction between effects of caffeine and lorazepam in performance tests and self-ratings. J Clin Psychopharmacol 1982;2:102-6. View abstract.
  69. Broughton LJ, Rogers HJ. Decreased systemic clearance of caffeine due to cimetidine. Br J Clin Pharmacol 1981;12:155-9. View abstract.
  70. Cesana M, Broccali G, Imbimbo BP, Crema A. Effect of single doses of rufloxacin on the disposition of theophylline and caffeine after single administration. Int J Clin Pharmacol Ther Toxicol 1991:29:133-8. View abstract.
  71. Zhang LL, Zhang JR, Guo K, et al. Effects of fluoroquinolones on CYP4501A and 3A in male broilers. Res Vet Sci 2011;90:99-105. View abstract.
  72. Harder S, Staib AH, Beer C, et al. 4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol 1988;35:651-6. View abstract.
  73. Azcona O, Barbanoi MJ, Torrent J, Jane F. Evaluation of the central effects of alcohol and caffeine interaction. Br J Clin Pharmacol 1995;40:393-400. View abstract.
  74. Zheng, J., Chen, B., Jiang, B., Zeng, L., Tang, Z. R., Fan, L., and Zhou, H. H. The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo. Arch Pharm Res 2010;33:243-246. View abstract.
  75. Chen, Y., Xiao, C. Q., He, Y. J., Chen, B. L., Wang, G., Zhou, G., Zhang, W., Tan, Z. R., Cao, S., Wang, L. P., and Zhou, H. H. Genistein alters caffeine exposure in healthy female volunteers. Eur.J Clin.Pharmacol. 2011;67:347-353. View abstract.
  76. Wang, X. and Yeung, J. H. Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats. J Pharm Pharmacol 2010;62:1077-1083. View abstract.
  77. Norager, C. B., Jensen, M. B., Weimann, A., and Madsen, M. R. Metabolic effects of caffeine ingestion and physical work in 75-year old citizens. A randomized, double-blind, placebo-controlled, cross-over study. Clin Endocrinol (Oxf) 2006;65:223-228. View abstract.
  78. Wojcikowski, J. and Daniel, W. A. Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism--an in vitro study. Pharmacol Rep. 2009;61:851-858. View abstract.
  79. Mays, D. C., Camisa, C., Cheney, P., Pacula, C. M., Nawoot, S., and Gerber, N. Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans. Clin.Pharmacol.Ther. 1987;42:621-626. View abstract.
  80. Mohiuddin, M., Azam, A. T., Amran, M. S., and Hossain, M. A. In vive effects of gliclazide and metformin on the plasma concentration of caffeine in healthy rats. Pak.J Biol Sci 5-1-2009;12:734-737. View abstract.
  81. Gasior, M., Swiader, M., Przybylko, M., Borowicz, K., Turski, W. A., Kleinrok, Z., and Czuczwar, S. J. Felbamate demonstrates low propensity for interaction with methylxanthines and Ca2+ channel modulators against experimental seizures in mice. Eur.J Pharmacol 7-10-1998;352(2-3):207-214. View abstract.
  82. Vaz, J., Kulkarni, C., David, J., and Joseph, T. Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers. Indian J.Exp.Biol. 1998;36:112-114. View abstract.
  83. Chroscinska-Krawczyk, M., Jargiello-Baszak, M., Walek, M., Tylus, B., and Czuczwar, S. J. Caffeine and the anticonvulsant potency of antiepileptic drugs: experimental and clinical data. Pharmacol.Rep. 2011;63:12-18. View abstract.
  84. Luszczki, J. J., Zuchora, M., Sawicka, K. M., Kozinska, J., and Czuczwar, S. J. Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. Pharmacol Rep. 2006;58:652-659. View abstract.
  85. Jankiewicz, K., Chroscinska-Krawczyk, M., Blaszczyk, B., and Czuczwar, S. J. [Caffeine and antiepileptic drugs: experimental and clinical data]. Przegl.Lek. 2007;64:965-967. View abstract.
  86. Gasior, M., Borowicz, K., Buszewicz, G., Kleinrok, Z., and Czuczwar, S. J. Anticonvulsant activity of phenobarbital and valproate against maximal electroshock in mice during chronic treatment with caffeine and caffeine discontinuation. Epilepsia 1996;37:262-268. View abstract.
  87. Kot, M. and Daniel, W. A. Effect of diethyldithiocarbamate (DDC) and ticlopidine on CYP1A2 activity and caffeine metabolism: an in vitro comparative study with human cDNA-expressed CYP1A2 and liver microsomes. Pharmacol Rep. 2009;61:1216-1220. View abstract.
  88. Stille, W., Harder, S., Mieke, S., Beer, C., Shah, P. M., Frech, K., and Staib, A. H. Decrease of caffeine elimination in man during co-administration of 4-quinolones. J.Antimicrob.Chemother. 1987;20:729-734. View abstract.
  89. Shet, M. S., McPhaul, M., Fisher, C. W., Stallings, N. R., and Estabrook, R. W. Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos. 1997;25:1298-1303. View abstract.
  90. Parker DL, Hoffmann TK, Tucker MA, et al. Interaction between warfarin and black tea. Ann Pharmacother 2009;43:150-1. View abstract.
  91. Savitz DA, Chan RL, Herring AH, et al. Caffeine and miscarriage risk. Epidemiology 2008;19:55-62. View abstract.
  92. Weng X, Odouli R, Li DK. Maternal caffeine consumption during pregnancy and the risk of miscarriage: a prospective cohort study. Am J Obstet Gynecol 2008;198:279.e1-8. View abstract.
  93. Fukuda I, Sakane I, Yabushita Y, et al. Black tea theaflavins suppress dioxin-induced transformation of the aryl hydrocarbon receptor. Biosci Biotechnol Biochem 2005;69:883-90. View abstract.
  94. Kundu T, Dey S, Roy M, et al. Induction of apoptosis in human leukemia cells by black tea and its polyphenol theaflavin. Cancer Lett 2005;230:111-21. View abstract.
  95. Way TD, Lee HH, Kao MC, Lin JK. Black tea polyphenol theaflavins inhibit aromatase activity and attenuate tamoxifen resistance in HER2/neu-transfected human breast cancer cells through tyrosine kinase suppression. Eur J Cancer 2004;40:2165-74. View abstract.
  96. Mizuno H, Cho YY, Zhu F, et al. Theaflavin-3, 3'-digallate induces epidermal growth factor receptor downregulation. Mol Carcinog 2006;45:204-12. View abstract.
  97. Chen CN, Lin CP, Huang KK, et al. Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3). Evid Based Complement Alternat Med 2005;2:209-15. View abstract.
  98. Liu S, Lu H, Zhao Q, et al. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta 2005;1723:270-81. View abstract.
  99. Tu YY, Tang AB, Watanabe N. The theaflavin monomers inhibit the cancer cells growth in vitro. Acta Biochim Biophys Sin (Shanghai) 2004;36:508-12. View abstract.
  100. Yanagida A, Shoji A, Shibusawa Y, et al. Analytical separation of tea catechins and food-related polyphenols by high-speed counter-current chromatography. J Chromatogr A 2006;1112:195-201. View abstract.
  101. Taubert D, Roesen R, Schomig E. Effect of cocoa and tea intake on blood pressure: a meta-analysis. Arch Intern Med 2007;167:626-34. View abstract.
  102. Lorenz M, Jochmann N, von Krosigk A, et al. Addition of milk prevents vascular protective effects of tea. Eur Heart J 2007;28:219-23. View abstract.
  103. Correa A, Stolley A, Liu Y. Prenatal tea consumption and risks of anencephaly and spina bifida. Ann Epidemiol 2000;10:476-7. View abstract.
  104. Kanis J, Johnell O, Gullberg B, et al. Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study. Osteoporos Int 1999;9:45-54. View abstract.
  105. Iso H, Date C, Wakai K, et al; JACC Study Group. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Ann Intern Med 2006;144:554-62. View abstract.
  106. Khokhar S, Magnusdottir SG. Total phenol, catechin, and caffeine contents of teas commonly consumed in the United kingdom. J Agric Food Chem 2002;50:565-70. View abstract.
  107. Robinson LE, Savani S, Battram DS, et al. Caffeine ingestion before an oral glucose tolerance test impairs blood glucose management in men with type 2 diabetes. J Nutr 2004;134:2528-33. View abstract.
  108. Lake CR, Rosenberg DB, Gallant S, et al. Phenylpropanolamine increases plasma caffeine levels. Clin Pharmacol Ther 1990;47:675-85. View abstract.
  109. Forrest WH Jr, Bellville JW, Brown BW Jr. The interaction of caffeine with pentobarbital as a nighttime hypnotic. Anesthesiology 1972;36:37-41. View abstract.
  110. Raaska K, Raitasuo V, Laitila J, Neuvonen PJ. Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic Clin Pharmacol Toxicol 2004;94:13-8. View abstract.
  111. Watson JM, Sherwin RS, Deary IJ, et al. Dissociation of augmented physiological, hormonal and cognitive responses to hypoglycaemia with sustained caffeine use. Clin Sci (Lond) 2003;104:447-54. View abstract.
  112. Winkelmayer WC, Stampfer MJ, Willett WC, Curhan GC. Habitual caffeine intake and the risk of hypertension in women. JAMA 2005;294:2330-5. View abstract.
  113. Juliano LM, Griffiths RR. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl) 2004;176:1-29. View abstract.
  114. Leson CL, McGuigan MA, Bryson SM. Caffeine overdose in an adolescent male. J Toxicol Clin Toxicol 1988;26:407-15. View abstract.
  115. Benowitz NL, Osterloh J, Goldschlager N, et al. Massive catecholamine release from caffeine poisoning. JAMA 1982;248:1097-8. View abstract.
  116. Scholey AB, Kennedy DO. Cognitive and physiological effects of an "energy drink:" an evaluation of the whole drink and of glucose, caffeine and herbal flavouring fractions. Psychopharmacology (Berl) 2004;176:320-30. View abstract.
  117. Haller CA, Benowitz NL, Jacob P 3rd. Hemodynamic effects of ephedra-free weight-loss supplements in humans. Am J Med 2005;118:998-1003.. View abstract.
  118. Larsson SC, Wolk A. Tea consumption and ovarian cancer risk in a population-based cohort. Arch Intern Med 2005;165:2683-6. View abstract.
  119. Schabath MB, Hernandez LM, Wu X, et al. Dietary phytoestrogens and lung cancer risk. JAMA 2005;294:1493-1504. View abstract.
  120. Gupta S, Saha B, Giri AK. Comparative antimutagenic and anticlastogenic effects of green tea and black tea: a review. Mutat Res 2002;512:37-65. View abstract.
  121. Petrie HJ, Chown SE, Belfie LM, et al. Caffeine ingestion increases the insulin response to an oral-glucose-tolerance test in obese men before and after weight loss. Am J Clin Nutr 2004;80:22-8. View abstract.
  122. Lane JD, Barkauskas CE, Surwit RS, Feinglos MN. Caffeine impairs glucose metabolism in type 2 diabetes. Diabetes Care 2004;27:2047-8. View abstract.
  123. Vinson JA, Teufel K, Wu N. Green and black teas inhibit atherosclerosis by lipid, antioxidant, and fibrinolytic mechanisms. J Agric Food Chem 2004;52:3661-5. View abstract.
  124. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003;18:343-51.. View abstract.
  125. Sato J, Nakata H, Owada E, et al. Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. Eur J Clin Pharmacol 1993;44:295-8. View abstract.
  126. Cannon ME, Cooke CT, McCarthy JS. Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products. Med J Aust 2001;174:520-1. View abstract.
  127. Durrant KL. Known and hidden sources of caffeine in drug, food, and natural products. J Am Pharm Assoc 2002;42:625-37. View abstract.
  128. Beach CA, Mays DC, Guiler RC, et al. Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. Clin Pharmacol Ther 1986;39:265-70. View abstract.
  129. Dews PB, O'Brien CP, Bergman J. Caffeine: behavioral effects of withdrawal and related issues. Food Chem Toxicol 2002;40:1257-61. View abstract.
  130. Holmgren P, Norden-Pettersson L, Ahlner J. Caffeine fatalities--four case reports. Forensic Sci Int 2004;139:71-3. View abstract.
  131. Chou T. Wake up and smell the coffee. Caffeine, coffee, and the medical consequences. West J Med 1992;157:544-53. View abstract.
  132. Howell LL, Coffin VL, Spealman RD. Behavioral and physiological effects of xanthines in nonhuman primates. Psychopharmacology (Berl) 1997;129:1-14. View abstract.
  133. Rakic V, Beilin LJ, Burke V. Effect of coffee and tea drinking on postprandial hypotension in older men and women. Clin Exp Pharmacol Physiol 1996;23:559-63. View abstract.
  134. Heseltine D, Dakkak M, woodhouse K, et al. The effect of caffeine on postprandial hypotension in the elderly. J Am Geriatr Soc 1991;39:160-4. View abstract.
  135. Castellanos FX, Rapoport JL. Effects of caffeine on development and behavior in infancy and childhood: a review of the published literature. Food Chem Toxicol 2002;40:1235-42. View abstract.
  136. Institute of Medicine. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington, DC: National Academy Press, 2001. Available at: http://books.nap.edu/books/0309082587/html/index.html.
  137. Zheng XM, Williams RC. Serum caffeine levels after 24-hour abstention: clinical implications on dipyridamole Tl myocardial perfusion imaging. J Nucl Med Technol 2002;30:123-7. View abstract.
  138. Aqel RA, Zoghbi GJ, Trimm JR, et al. Effect of caffeine administered intravenously on intracoronary-administered adenosine-induced coronary hemodynamics in patients with coronary artery disease. Am J Cardiol 2004;93:343-6. View abstract.
  139. Underwood DA. Which medications should be held before a pharmacologic or exercise stress test? Cleve Clin J Med 2002;69:449-50. View abstract.
  140. Smith A. Effects of caffeine on human behavior. Food Chem Toxicol 2002;40:1243-55. View abstract.
  141. Stanek EJ, Melko GP, Charland SL. Xanthine interference with dipyridamole-thallium-201 myocardial imaging. Pharmacother 1995;29:425-7. View abstract.
  142. Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000;39:127-53. View abstract.
  143. Wahllander A, Paumgartner G. Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. Eur J Clin Pharmacol 1989;37:279-83. View abstract.
  144. Sanderink GJ, Bournique B, Stevens J, et al. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. Pharmacol Exp Ther 1997;282:1465-72. View abstract.
  145. Brown NJ, Ryder D, Branch RA. A pharmacodynamic interaction between caffeine and phenylpropanolamine. Clin Pharmacol Ther 1991;50:363-71. View abstract.
  146. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985;28:425-8. View abstract.
  147. May DC, Jarboe CH, VanBakel AB, Williams WM. Effects of cimetidine on caffeine disposition in smokers and nonsmokers. Clin Pharmacol Ther 1982;31:656-61. View abstract.
  148. Nawrot P, Jordan S, Eastwood J, et al. Effects of caffeine on human health. Food Addit Contam 2003;20:1-30. View abstract.
  149. Massey LK, Whiting SJ. Caffeine, urinary calcium, calcium metabolism and bone. J Nutr 1993;123:1611-4. View abstract.
  150. Infante S, Baeza ML, Calvo M, et al. Anaphylaxis due to caffeine. Allergy 2003;58:681-2. View abstract.
  151. Maron DJ, Lu GP, Cai NS, et al. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. Arch Intern Med 2003;163:1448-53.. View abstract.
  152. Greenblatt DJ, von Moltke LL, Perloff ES, et al. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther 2006;79:125-33. View abstract.
  153. Nix D, Zelenitsky S, Symonds W, et al. The effect of fluconazole on the pharmacokinetics of caffeine in young and elderly subjects. Clin Pharmacol Ther 1992;51:183.
  154. Johnell O, Gullberg B, Kanis JA. Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res 1995;10:1802-15.. View abstract.
  155. Kockler DR, McCarthy MW, Lawson CL. Seizure activity and unresponsiveness after hydroxycut ingestion. Pharmacotherapy 2001;21:647-51.. View abstract.
  156. Grandjean AC, Reimers KJ, Bannick KE, Haven MC. The effect of caffeinated, non-caffeinated, caloric and non-caloric beverages on hydration. J Am Coll Nutr 2000;19:591-600.. View abstract.
  157. Kamimori GH, Penetar DM, Headley DB, et al. Effect of three caffeine doses on plasma catecholamines and alertness during prolonged wakefulness. Eur J Clin Pharmacol 2000;56:537-44.. View abstract.
  158. Dreher HM. The effect of caffeine reduction on sleep quality and well-being in persons with HIV. J Psychosom Res 2003;54:191-8.. View abstract.
  159. Massey LK. Is caffeine a risk factor for bone loss in the elderly? Am J Clin Nutr 2001;74:569-70. View abstract.
  160. Warburton DM, Bersellini E, Sweeney E. An evaluation of a caffeinated taurine drink on mood, memory and information processing in healthy volunteers without caffeine abstinence. Psychopharmacology (Berl) 2001;158:322-8.. View abstract.
  161. Nehlig A, Debry G. Consequences on the newborn of chronic maternal consumption of coffee during gestation and lactation: a review. J Am Coll Nutr 1994;13:6-21.. View abstract.
  162. McGowan JD, Altman RE, Kanto WP Jr. Neonatal withdrawal symptoms after chronic maternal ingestion of caffeine. South Med J 1988;81:1092-4.. View abstract.
  163. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003;289:1537-45.. View abstract.
  164. Bara AI, Barley EA. Caffeine for asthma. Cochrane Database Syst Rev 2001;4:CD001112.. View abstract.
  165. Bracken MB, Triche EW, Belanger K, et al. Association of maternal caffeine consumption with decrements in fetal growth. Am J Epidemiol 2003;157:456-66.. View abstract.
  166. Temme EH, Van Hoydonck PG. Tea consumption and iron status. Eur J Clin Nutr 2002;56:379-86.. View abstract.
  167. Checkoway H, Powers K, Smith-Weller T, et al. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002;155:732-8.. View abstract.
  168. Michels KB, Holmberg L, Bergkvist L, Wolk A. Coffee, tea, and caffeine consumption and breast cancer incidence in a cohort of Swedish women. Ann Epidemiol 2002;12:21-6. View abstract.
  169. Su LJ, Arab L. Tea consumption and the reduced risk of colon cancer -- results from a national prospective cohort study. Public Health Nutr 2002;5:419-25.. View abstract.
  170. Terry P, Wolk A. Tea consumption and the risk of colorectal cancer in Sweden. Nutr Cancer 2001;39:176-9.. View abstract.
  171. Leung LK, Su Y, Chen R, et al. Theaflavins in black tea and catechins in green tea are equally effective antioxidants. J Nutr 2001;131:2248-51.. View abstract.
  172. de Maat MP, Pijl H, Kluft C, Princen HM. Consumption of black and green tea had no effect on inflammation, haemostasis and endothelial markers in smoking healthy individuals. Eur J Clin Nutr 2000;54:757-63.. View abstract.
  173. Hodgson JM, Croft KD, Mori TA, et al. Regular ingestion of tea does not inhibit in vivo lipid peroxidation in humans. J Nutr 2002;132:55-8.. View abstract.
  174. Zhang M, Binns CW, Lee AH. Tea consumption and ovarian cancer risk: a case-control study in China. Cancer Epidemiol Biomarkers Prev 2002;11:713-8.. View abstract.
  175. Choi YT, Jung CH, Lee SR, et al. The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci 2001;70:603-14.. View abstract.
  176. Tajima K, Tominaga S. Dietary habits and gastro-intestinal cancers: a comparative case-control study of stomach and large intestinal cancers in Nagoya, Japan. Jpn J Cancer Res 1985;76:705-16.. View abstract.
  177. Inoue M, Tajima K, Hirose K, et al. Tea and coffee consumption and the risk of digestive tract cancers: data from a comparative case-referent study in Japan. Cancer Causes Control 1998;9:209-16.. View abstract.
  178. Horner NK, Lampe JW. Potential mechanisms of diet therapy for fibrocystic breast conditions show inadequate evidence of effectiveness. J Am Diet Assoc 2000;100:1368-80. View abstract.
  179. Duffy SJ, Vita JA, Holbrook M, et al. Effect of acute and chronic tea consumption on platelet aggregation in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:1084-9. View abstract.
  180. Zijp IM, Korver O, Tijburg LB. Effect of tea and other dietary factors on iron absorption. Crit Rev Food Sci Nutr 2000;40:371-98. View abstract.
  181. Bell DG, Jacobs I, Ellerington K. Effect of caffeine and ephedrine ingestion on anaerobic exercise performance. Med Sci Sports Exerc 2001;33:1399-403. View abstract.
  182. Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. Ann Pharmacother 2002;36:992-5.. View abstract.
  183. Esimone CO, Adikwu MU, Nwafor SV, Okolo CO. Potential use of tea extract as a complementary mouthwash: comparative evaluation of two commercial samples. J Altern Complement Med 2001;7:523-7. View abstract.
  184. Shahrzad S, Aoyagi K, Winter A, et al. Pharmacokinetics of gallic acid and its relative bioavailability from tea in healthy humans. J Nutr 2001;131:1207-10. View abstract.
  185. Geleijnse JM, Witteman JC, Launer LJ, et al. Tea and coronary heart disease: protection through estrogen-like activity? Arch Intern Med 2000;160:3328-9. View abstract.
  186. Peters U, Poole C, Arab L. Does tea affect cardiovascular disease? A meta-analysis. Am J Epidemiol 2001;154:495-503. View abstract.
  187. Mukamal KJ, Maclure M, Muller JE, et al. Tea consumption and mortality after acute myocardial infarction. Circulation 2002;105:2476-81. View abstract.
  188. Geleijnse JM, Launer LJ, van der Kuip DA, et al. Inverse association of tea and flavonoid intakes with incident myocardial infarction: the Rotterdam Study. Am J Clin Nutr 2002;75:880-6. View abstract.
  189. Wu CH, Yang YC, Yao WJ, et al. Epidemiological evidence of increased bone mineral density in habitual tea drinkers. Arch Intern Med 2002;162:1001-6. View abstract.
  190. Cronin JR. Green tea extract stokes thermogenesis: will it replace ephedra? Altern Comp Ther 2000;6:296-300.
  191. Ferrini RL, Barrett-Connor E. Caffeine intake and endogenous sex steroid levels in postmenopausal women. The Rancho Bernardo Study. Am J Epidemiol 1996:144:642-4. View abstract.
  192. Hartman TJ, Tangrea JA, Pietinen P, et al. Tea and coffee consumption and risk of colon and rectal cancer in middle-aged Finnish men. Nutr Cancer 1998;31:41-8. View abstract.
  193. Olthof MR, Hollman PC, Zock PL, Katan MB. Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans. Am J Clin Nutr 2001;73:532-8. View abstract.
  194. Ardlie NG, Glew G, Schultz BG, Schwartz CJ. Inhibition and reversal of platelet aggregation by methyl xanthines. Thromb Diath Haemorrh 1967;18:670-3. View abstract.
  195. Ali M, Afzal M. A potent inhibitor of thrombin stimulated platelet thromboxane formation from unprocessed tea. Prostaglandins Leukot Med 1987;27:9-13. View abstract.
  196. Hertog MG, Feskens EJ, Hollman PC, et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007-1011. View abstract.
  197. Keli SO, Hertog MG, Feskens EJ, Kromhout D. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch Intern Med 1996;156:637-42. View abstract.
  198. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833-8. View abstract.
  199. Hegarty VM, May HM, Khaw K. Tea drinking and bone mineral density in older women. Am J Clin Nutr 2000;71:1003-7. View abstract.
  200. Sinclair CJ, Geiger JD. Caffeine use in sports. A pharmacological review. J Sports Med Phys Fitness 2000;40:71-9. View abstract.
  201. Hodgson JM, Puddey IB, Croft KD, et al. Acute effects of ingestion of black and green tea on lipoprotein oxidation. Am J Clin Nutr 2000;71:1103-7. View abstract.
  202. Leenen R, Roodenburg AJ, Tijburg LB, et al. A single dose of tea with or without milk increases plasma antioxidant activity in humans. Eur J Clin Nutr 2000;54:87-92. View abstract.
  203. American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89. View abstract.
  204. Lloyd T, Johnson-Rollings N, Eggli DF, et al. Bone status among postmenopausal women with different habitual caffeine intakes: a longitudinal investigation. J Am Coll Nutr 2000;19:256-61. View abstract.
  205. Watson JM, Jenkins EJ, Hamilton P, et al. Influence of caffeine on the frequency and perception of hypoglycemia in free-living patients with type 1 diabetes. Diabetes Care 2000;23:455-9. View abstract.
  206. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of parkinson disease. JAMA 2000;283:2674-9. View abstract.
  207. Hagg S, Spigset O, Mjorndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2000;49:59-63. View abstract.
  208. Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at: http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid= 786bafc6f6343634fbf79fcdca7061e1&rgn=div5&view= text&node=21:3.0.1.1.13&idno=21
  209. Williams MH, Branch JD. Creatine supplementation and exercise performance: an update. J Am Coll Nutr 1998;17:216-34. View abstract.
  210. Briggs GB, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.
  211. Hindmarch I, Quinlan PT, Moore KL, Parkin C. The effects of black tea and other beverages on aspects of cognition and psychomotor performance. Psychopharmacol 1998;139:230-8. View abstract.
  212. Sesso HD, Gaziano JM, Buring JE, et al. Coffee and tea intake and the risk of myocardial infarction. Am J Epidemiol 1999;149:162-7. View abstract.
  213. Durlach PJ. The effects of a low dose of caffeine on cognitive performance. Psychopharmacology (Berl) 1998;140:116-9. View abstract.
  214. Kaegi E. Unconventional therapies for cancer: 2. Green tea. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 1998;158:1033-5. View abstract.
  215. Curhan GC, Willett WC, Speizer FE, Stamfer MJ. Beverage use and risk of kidney stones in women. Ann Intern Med 1998;128:534-40. View abstract.
  216. Weisburger JH. Tea and health: the underlying mechanisms. Proc Soc Exp Biol Med 1999;220:271-5. View abstract.
  217. Geleijnse JM, Launer LJ, Hofman A, et al. Tea flavonoids may protect against atherosclerosis: the Rotterdam Study. Arch Intern Med 1999;159:2170-4. View abstract.
  218. FDA. Proposed rule: dietary supplements containing ephedrine alkaloids. Available at: www.verity.fda.gov (Accessed 25 January 2000).
  219. Dews PB, Curtis GL, Hanford KJ, O'Brien CP. The frequency of caffeine withdrawal in a population-based survey and in a controlled, blinded pilot experiment. J Clin Pharmacol 1999;39:1221-32. View abstract.
  220. Nurminen ML, Niittynen L, Korpela R, Vapaatalo H. Coffee, caffeine and blood pressure: a critical review. Eur J Clin Nutr 1999;53:831-9. View abstract.
  221. Migliardi JR, Armellino JJ, Friedman M, et al. Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 1994;56:576-86. View abstract.
  222. Pollock BG, Wylie M, Stack JA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol 1999;39:936-40. View abstract.
  223. Wemple RD, Lamb DR, McKeever KH. Caffeine vs caffeine-free sports drinks: effects on urine production at rest and during prolonged exercise. Int J Sports Med 1997;18:40-6. View abstract.
  224. Stookey JD. The diuretic effects of alcohol and caffeine and total water intake misclassification. Eur J Epidemiol 1999;15:181-8. View abstract.
  225. Fernandes O, Sabharwal M, Smiley T, et al. Moderate to heavy caffeine consumption during pregnancy and relationship to spontaneous abortion and abnormal fetal growth: a meta-analysis. Reprod Toxicol 1998;12:435-44. View abstract.
  226. Eskenazi B. Caffeine—filtering the facts. N Engl J Med 1999;341:1688-9. View abstract.
  227. Klebanoff MA, Levine RJ, DerSimonian R, et al. Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion. N Engl J Med 1999;341:1639-44. View abstract.
  228. The National Toxicology Program (NTP). Caffeine. Center for the Evaluation of Risks to Human Reproduction (CERHR). Available at: http://cerhr.niehs.nih.gov/common/caffeine.html.
  229. Rapuri PB, Gallagher JC, Kinyamu HK, Ryschon KL. Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr 2001;74:694-700. View abstract.
  230. Chiu KM. Efficacy of calcium supplements on bone mass in postmenopausal women. J Gerontol A Biol Sci Med Sci 1999;54:M275-80. View abstract.
  231. Vandeberghe K, Gillis N, Van Leemputte M, et al. Caffeine counteracts the ergogenic action of muscle creatine loading. J Appl Physiol 1996;80:452-7. View abstract.
  232. Wallach J. Interpretation of Diagnostic Tests. A synopsis of Laboratory Medicine. Fifth ed; Boston, MA: Little Brown, 1992.
  233. Hodgson JM, Puddey IB, Burke V, et al. Effects on blood pressure of drinking green and black tea. J Hypertens 1999;17:457-63. View abstract.
  234. Wakabayashi K, Kono S, Shinchi K, et al. Habitual coffee consumption and blood pressure: A study of self-defense officials in Japan. Eur J Epidemiol 1998;14:669-73. View abstract.
  235. Vahedi K, Domingo V, Amarenco P, Bousser MG. Ischemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for bodybuilding. J Neurol Neurosurg Psychiatr 2000;68:112-3. View abstract.
  236. Joeres R, Klinker H, Heusler H, et al. Influence of mexiletine on caffeine elimination. Pharmacol Ther 1987;33:163-9. View abstract.
  237. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine intake and risk of Parkinson's disease in men and women. Proceedings 125th Ann Mtg Am Neurological Assn. Boston, MA: 2000;Oct 15-18:42 (abstract 53).
  238. Merhav H, Amitai Y, Palti H, Godfrey S. Tea drinking and microcytic anemia in infants. Am J Clin Nutr 1985;41:1210-3. View abstract.
  239. Kulhanek F, Linde OK, Meisenberg G. Precipitation of antipsychotic drugs in interaction with coffee or tea. Lancet 1979;2:1130. View abstract.
  240. Lasswell WL Jr, Weber SS, Wilkins JM. In vitro interaction of neuroleptics and tricylic antidepressants with coffee, tea, and gallotannic acid. J Pharm Sci 1984;73:1056-8. View abstract.
  241. Jefferson JW. Lithium tremor and caffeine intake: two cases of drinking less and shaking more. J Clin Psychiatry 1988;49:72-3. View abstract.
  242. Mester R, Toren P, Mizrachi I, et al. Caffeine withdrawal increases lithium blood levels. Biol Psychiatry 1995;37:348-50. View abstract.
  243. Healy DP, Polk RE, Kanawati L, et al. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother 1989;33:474-8. View abstract.
  244. Carbo M, Segura J, De la Torre R, et al. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther 1989;45:234-40. View abstract.
  245. Harder S, Fuhr U, Staib AH, Wolff T. Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. Am J Med 1989;87:89S-91S. View abstract.
  246. Foster S, Duke JA. Eastern/Central Medicinal Plants. New York, NY: Houghton Mifflin Co., 1990.
  247. Hertog MGL, Sweetnam PM, Fehily AM, et al. Antioxidant flavonols and ischemic heart disease in a Welsh population of men: the Caerphilly Study. Am J Clin Nutr 1997;65:1489-94. View abstract.
  248. McKevoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
Show more references
Show fewer references
Last reviewed - 11/11/2014




Page last updated: 10 December 2014